Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis

Overview of attention for article published in Respiratory Research, March 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (62nd percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter: 7 X users

Citations

dimensions_citation: 19 Dimensions

Readers on

mendeley: 50 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 10 X posts from 7 X users, with an upper bound of 5,717 followers.

RT @ATS_GG: Sputum and Blood Transcriptomics Characterisation of the Inhaled PDE4 Inhibitor CHF6001 on Top of Triple Therapy in Patients Wi…

30 Jun 2020

Reply Repost Favourite

RT @ATS_GG: Sputum and Blood Transcriptomics Characterisation of the Inhaled PDE4 Inhibitor CHF6001 on Top of Triple Therapy in Patients Wi…

30 Jun 2020

Reply Repost Favourite

RT @ATS_GG: Sputum and Blood Transcriptomics Characterisation of the Inhaled PDE4 Inhibitor CHF6001 on Top of Triple Therapy in Patients Wi…

30 Jun 2020

Reply Repost Favourite

Sputum and Blood Transcriptomics Characterisation of the Inhaled PDE4 Inhibitor CHF6001 on Top of Triple Therapy in Patients With Chronic Bronchitis https://t.co/L3wppghSZW

29 Jun 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.